In situ vaccination for the treatment of cancer

被引:85
作者
Hammerich, Linda [1 ]
Bhardwaj, Nina [1 ]
Kohrt, Holbrook E. [2 ]
Brody, Joshua D. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[2] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA
关键词
autologous DC; cytokine; Flt3L; in situ vaccine; oncolytic virus; TLR agonist; tumor-associated antigen; COLONY-STIMULATING FACTOR; HERPES-SIMPLEX-VIRUS; TUMOR-ASSOCIATED VASCULATURE; ENHANCES ANTITUMOR EFFICACY; TARGETED ONCOLYTIC POXVIRUS; LOW-DOSE CYCLOPHOSPHAMIDE; FOLLICLE CENTER LYMPHOMA; RENAL-CELL CARCINOMA; INTRATUMORAL INJECTION; DENDRITIC CELLS;
D O I
10.2217/imt.15.120
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination has had a tremendous impact on human health by harnessing the immune system to prevent and eradicate infectious diseases and this same approach might be used in cancer therapy. Cancer vaccine development has been slowed hindered by the paucity of universal tumor-associated antigens and the difficulty in isolating and preparing individualized vaccines ex vivo. Another approach has been to initiate or stimulate an immune response in situ (at the tumor site) and thus exploit the potentially numerous tumor-associated antigens there. Here, we review the many approaches that have attempted to accomplish effective in situ vaccination, using intratumoral administration of immunomodulators to increase the numbers or activation state of either antigen present cells or T cells within the tumor.
引用
收藏
页码:315 / 330
页数:16
相关论文
共 153 条
[1]   Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer [J].
Adams, Sylvia ;
Kozhaya, Lina ;
Martiniuk, Frank ;
Meng, Tze-Chiang ;
Chiriboga, Luis ;
Liebes, Leonard ;
Hochman, Tsivia ;
Shuman, Nicholas ;
Axelrod, Deborah ;
Speyer, James ;
Novik, Yelena ;
Tiersten, Amy ;
Goldberg, Judith D. ;
Formenti, Silvia C. ;
Bhardwaj, Nina ;
Unutmaz, Derya ;
Demaria, Sandra .
CLINICAL CANCER RESEARCH, 2012, 18 (24) :6748-6757
[2]   Oncolytic Adenoviruses in Cancer Treatment [J].
Alemany, Ramon .
BIOMEDICINES, 2014, 2 (01) :36-49
[3]   Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice [J].
Amos, Sally M. ;
Pegram, Hollie J. ;
Westwood, Jennifer A. ;
John, Liza B. ;
Devaud, Christel ;
Clarke, Chris J. ;
Restifo, Nicholas P. ;
Smyth, Mark J. ;
Darcy, Phillip K. ;
Kershaw, Michael H. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (05) :671-683
[4]  
[Anonymous], J CLIN ONCOL S5S
[5]  
Ardigo M, 2006, EUR J DERMATOL, V16, P446
[6]   Treatment of mycosis fungoides with imiquimod 5% cream [J].
Ariffin, N. ;
Khorshid, M. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2006, 31 (06) :822-823
[7]   Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model [J].
Banissi, Claire ;
Ghiringhelli, Francois ;
Chen, Lin ;
Carpentier, Antoine F. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) :1627-1634
[8]   Oncolytic viruses as therapeutic cancer vaccines [J].
Bartlett, David L. ;
Liu, Zuqiang ;
Sathaiah, Magesh ;
Ravindranathan, Roshni ;
Guo, Zongbi ;
He, Yukai ;
Guo, Zong Sheng .
MOLECULAR CANCER, 2013, 12
[9]   Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [J].
Bendandi, M ;
Gocke, CD ;
Kobrin, CB ;
Benko, FA ;
Sternas, LA ;
Pennington, R ;
Watson, TM ;
Reynolds, CW ;
Gause, BL ;
Duffey, PL ;
Jaffe, ES ;
Creekmore, SP ;
Longo, DL ;
Kwak, LW .
NATURE MEDICINE, 1999, 5 (10) :1171-1177
[10]   Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures [J].
Bendandi, Maurizio .
NATURE REVIEWS CANCER, 2009, 9 (09) :675-681